Challenge Your Exam Readiness With Our Free AOCNP Practice Questions

Anthracyclines and HER2-targeted agents carry well-known cardiotoxic risks. Standard practice is to obtain a baseline assessment of left ventricular ejection fraction (LVEF), typically via transthoracic echocardiography, and to schedule periodic monitoring during and after therapy—more frequently when sequential anthracycline → trastuzumab is planned and when patient risk factors exist (hypertension, obesity, age). BP optimization, avoidance of cumulative doxorubicin doses above accepted thresholds, and attention to other cardiometabolic risks reduce events. Cardio-oncology collaboration is useful if LVEF is borderline or cardiac biomarkers (troponin/NT-proBNP) are abnormal. Amiodarone (Option C) is not cardioprotective and introduces toxicity. Switching to pertuzumab (Option D) does not remove the need for trastuzumab in standard regimens and does not eliminate HER2-therapy cardiac risk. Proceeding with only ECG (Option A) fails to quantify systolic function. The APRN ensures informed consent regarding cardiac risk, coordinates imaging schedules, counsels on symptom reporting (dyspnea, edema), and facilitates rapid evaluation for suspected cardiomyopathy with timely treatment modification and guideline-directed cardiac care if dysfunction occurs.